2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
04/04/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on April 2, 2018 it issued inducement awards to five new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides... 
Printer Friendly Version
03/28/18Multiple New Studies Demonstrate T2 Biosystems’ Diagnostics Improve Detection of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics
U.S. and EU studies demonstrate that T2Dx diagnostics enable getting patients on the right therapy faster, improving outcomes, enhancing stewardship, and reducing the cost of care LEXINGTON, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products, announces the publication of four new, peer-reviewed studies that demonstrate the clinical and performance advantages of the T... 
Printer Friendly Version
03/19/18T2 Biosystems to Present at the 17th Annual Needham Healthcare Conference
LEXINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John McDonough, president and chief executive officer is scheduled to present at the 17th Annual Needham Healthcare Conference.  The conference is being held March 27-28 at the Westin Grand Central Hotel in New York. The Company is scheduled to ... 
Printer Friendly Version
03/07/18T2 Biosystems Reports Granting of Inducement Award
LEXINGTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it issued an inducement award to John Sprague, the Company’s recently appointed Chief Financial Officer, in accordance with the terms of Mr. Sprague’s employment offer letter. The award was made on March 1, 2018 under T2 Biosystems’ Inducement A... 
Printer Friendly Version
03/06/18T2 Biosystems Reports Fourth Quarter and Full-Year 2017 Financial Results and Business Update
Quarterly Product Revenue Up 125% Year-Over-Year and 76% Over the Prior Quarter LEXINGTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the fourth quarter and year ended December 31, 2017.   Fourth Quarter Business and Financial Performance Highlights: ... 
Printer Friendly Version
03/06/18T2 Biosystems Awarded Up To $2 Million by CARB-X to Support Development of New Tests on the T2Dx Instrument for Drug-Resistant Bacteria
New tests aim to expand T2Dx Instrument product line by detecting 20 additional bacterial species and resistance targets that could empower doctors to rapidly treat more patients with targeted therapyLEXINGTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it has been awarded a grant of up to $2 milli... 
Printer Friendly Version
02/20/18T2 Biosystems Announces 2017 Fourth Quarter and Full-Year Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2017 fourth quarter and full-year financial and operational results after the market closes on Tuesday, March 6, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30... 
Printer Friendly Version
02/09/18Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing
Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy LEXINGTON, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, is announcing the release of two new peer-reviewed publications that demonstrate the superior performance of the T2Candida® Panel over blood culture and the capability of the T... 
Printer Friendly Version
02/06/18T2 Biosystems to Present at the 7th Annual Leerink Partners Global Healthcare Conference
LEXINGTON, Mass., Feb. 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John McDonough, president and chief executive officer is scheduled to present at the 7th Annual Leerink Partners Global Healthcare Conference.  The conference is being held February 14-15 at the Lotte New York Palace Hotel in New York.   The Company is scheduled to present on T... 
Printer Friendly Version
02/05/18T2 Biosystems Announces CFO Transition
LEXINGTON, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John Sprague has been named chief financial officer. Mr. Sprague is a highly accomplished financial executive who brings an extensive array of financial experience to T2 Biosystems, including a demonstrated success and leadership in building out companies during high-growth per... 
Printer Friendly Version
01/04/18T2 Biosystems Announces Preliminary Fourth Quarter 2017 Financial Results and Provides Update on T2Bacteria Panel
FDA Clearance of T2Bacteria® Panel remains on track for first quarter 2018 Total revenue expected to exceed the high end of guidance LEXINGTON, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced preliminary revenue and business results for the three months ended December 31, 2017 and provided an update on its 510(k) filing with the U.S. Food... 
Printer Friendly Version